The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution

  1. Gui-Zhen Wang
  2. Xin Cheng
  3. Bo Zhou
  4. Zhe-Sheng Wen
  5. Yun-Chao Huang
  6. Hao-Bin Chen
  7. Gao-Feng Li
  8. Zhi-Liang Huang
  9. Yong-Chun Zhou
  10. Lin Feng
  11. Ming-Ming Wei
  12. Li-Wei Qu
  13. Yi Cao
  14. Guang-Biao Zhou  Is a corresponding author
  1. University of Chinese Academy of Sciences, China
  2. Sun Yat-Sen University, China
  3. Kunming Medical University, China
  4. The First People's Hospital of Qujing, China
  5. The People's Liberation Army General Hospital, China
  6. Chinese Academy of Sciences, China

Abstract

More than 90% of lung cancers are caused by cigarette smoke and air pollution, with polycyclic aromatic hydrocarbons (PAHs) as key carcinogens. In Xuanwei City of Yunnan Province the lung cancer incidence is among the highest in China attributed to smoky coal combustion-generated PAH pollution. Here we screened for abnormal inflammatory factors in non-small cell lung cancers (NSCLCs) from Xuanwei and control regions (CR) where smoky coal was not used, and found that a chemokine CXCL13 was overexpressed in 63/70 (90%) of Xuanwei NSCLCs and 44/71 (62%) of smoker and 27/60 (45%) of non-smoker CR patients. CXCL13 overexpression was associated with the region Xuanwei and cigarette smoke. The key carcinogen bezo(a)pyrene (BaP) induced CXCL13 production in lung epithelial cells and in mice prior to development of detectable lung cancer. Deficiency in cxcl13 or its receptor, cxcr5, abrogated BaP-induced lung cancer in mice, demonstrating CXCL13's critical role in PAH-induced lung carcinogenesis.

Article and author information

Author details

  1. Gui-Zhen Wang

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Xin Cheng

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Bo Zhou

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Zhe-Sheng Wen

    Department of Thoracic Surgery, Cancer Center, Sun Yat-Sen University, Guangzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Yun-Chao Huang

    Department of Thoracic Surgery, Yunnan Tumor Hospital, Kunming Medical University, Kunming, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Hao-Bin Chen

    Department of Pathology, The First People's Hospital of Qujing, Qujing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Gao-Feng Li

    Department of Thoracic Surgery, Yunnan Tumor Hospital, Kunming Medical University, Kunming, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Zhi-Liang Huang

    Department of Thoracic Surgery, Cancer Center, Sun Yat-Sen University, Guangzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Yong-Chun Zhou

    Department of Thoracic Surgery, Yunnan Tumor Hospital, Kunming Medical University, Kunming, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Lin Feng

    Department of Pathology, The People's Liberation Army General Hospital, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Ming-Ming Wei

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Li-Wei Qu

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  13. Yi Cao

    Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Guang-Biao Zhou

    State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Beijing, China
    For correspondence
    gbzhou@ioz.ac.cn
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: Animal studies were conducted according to protocols approved by the Animal Ethics Committee of the Institute of Zoology, Chinese Academy of Sciences, with the approval ID of AEC2010070202.

Human subjects: The study was approved by the local research ethics committees of all participating sites; all lung cancer samples were collected with informed consent.

Copyright

© 2015, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,585
    views
  • 839
    downloads
  • 68
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gui-Zhen Wang
  2. Xin Cheng
  3. Bo Zhou
  4. Zhe-Sheng Wen
  5. Yun-Chao Huang
  6. Hao-Bin Chen
  7. Gao-Feng Li
  8. Zhi-Liang Huang
  9. Yong-Chun Zhou
  10. Lin Feng
  11. Ming-Ming Wei
  12. Li-Wei Qu
  13. Yi Cao
  14. Guang-Biao Zhou
(2015)
The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution
eLife 4:e09419.
https://doi.org/10.7554/eLife.09419

Share this article

https://doi.org/10.7554/eLife.09419

Further reading

    1. Cancer Biology
    Yiwei Huang, Gujie Wu ... Cheng Zhan
    Research Article

    Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.